No Rise in Suicides Found In Mania-Treatment Trials
With appropriate precautions, placebo-controlled trials of treatment for acute manic episodes and for prevention of manic-depressive episodes can be conducted with minimal risk of suicide.
So report Jitschak Storosum, M.D., Ph.D., and colleagues in the April American Journal of Psychiatry.
In a review of placebo-controlled, double-blind, randomized trials of medication for the treatment of acute manic episodes and the prevention of manic-depressive episodes, they found that suicide was not a significant risk among patients enrolled in placebo groups.
“The results... indicate no greater risk of suicide among patients with acute manic episode or stabilized bipolar disorder who were treated with placebo compared with the risk of patients who were treated with an active compound under the conditions of the trials,” Storosum wrote.
He is with the Medicines Evaluation Board of the Netherlands (a regulatory agency similar to the U.S. Food and Drug Administration).
In the study, all placebo-controlled, double-blind, randomized trials of medications for the treatment of acute manic episode and the prevention of manic-depressive episode that were part of a registration dossier submitted to the Medicines Evaluation Board between 1997 and 2003 were reviewed for occurrence of suicide and suicide attempts.
In 11 placebo-controlled studies of the treatment for acute manic episode that included 1,506 patients in active compound groups and 1,005 patients in placebo groups, Storosum and colleagues found no suicides and no suicide attempts in either group.
In four placebo-controlled studies of the prevention of manic-depressive episode that included 943 patients in active-compound groups and 418 patients in the combined placebo groups, there were no suicides and only two suicide attempts among the patients in placebo groups.
In the active-compound groups in those prevention trials, there were two suicides and eight suicide attempts, according to the report.
Storosum stated that one limitation to the study is the exclusion from placebo-controlled trials of patients who are considered at risk for suicide. But he noted that the suicide rate in the active-treatment arms of the prevention studies was greater than that reported by Frederick Goodwin, M.D., and colleagues in “Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex,” published in the September 2003 JAMA.
This “indicates that patients with bipolar disorder are at high risk for suicide, even if they are considered nonsuicidal and treated with an active compound,” Storosum and colleagues said.
Psychiatrist Maria Oquendo, M.D., who reviewed the report for Psychiatric News, called it a “very well done” study that complements similar studies that Storosum has done looking at suicide risk in placebo-controlled studies of treatment for schizophrenia and depression.
“These studies all show the same thing—that placebo groups do not have an increased risk for suicide,” said Oquendo, a clinical professor of psychiatry at Columbia University College of Physicians and Surgeons.
But she emphasized that researchers performing intervention studies continue to be ethically bound not to include patients at risk for suicide in placebo-controlled trials, and for that reason Storosum's conclusions about the relative safety of placebo cannot be extended yet to high-risk patients.
“As more and more data accumulate, we may be able to change that,” she said. “But until we have more evidence, we are ethically bound to exclude patients at risk for suicide from these studies.”
Oquendo published a report in the August 2004 American Journal of Psychiatry examining strategies for designing randomized, controlled trials that minimize the risk of morbidity and mortality for suicidal patients while providing valuable data on effectiveness of interventions (Psychiatric News, October 1, 2004).
Among her recommendations was not to use placebo controls in such intervention trials. Other strategies:
•
Use of surrogate outcome measures to protect subjects from actual suicidal acts.
•
Implementation of psychosocial interventions to monitor for exacerbation or increased risk.
•
Close monitoring of patients.
•
Retention of subjects in the study protocol in the event of hospitalization.
•
Early detection of large effect sizes.
“Suicide Risk in Placebo-Controlled Trials of Treatment for Acute Manic Episode and Prevention of Manic-Depressive Episode” is posted online at<http://ajp.psychiatryonline.org/cgi/content/full/162/4/799>.“ Prospective Study of Clinical Predictors of Suicidal Acts After a Major Depressive Episode in Patients With Major Depressive Disorder or Bipolar Disorder” is posted at<http://ajp.psychiatryonline.org/cgi/content/full/161/8/1433>.▪
Am J Psychiatry 2005 162 799
Am J Psychiatry 2004 161 1433
Information & Authors
Information
Published In
History
Published online: 20 May 2005
Published in print: May 20, 2005
Notes
But researchers performing intervention studies continue to be ethically bound not to include patients at risk for suicide in placebo-controlled trials.
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).